Immunicum AB (publ) today reports a significantly improved vaccine cell handling and gives a status update from the ongoing phase II study (MERECA) with the cancer immune primer INTUVAX in patients with metastatic renal cell carcinoma. Twelve patients have thus far been included in the study. So far, no serious vaccine-related adverse events have been reported. Immunological data, based on infiltration of CD8 + T cells in the tumors and in healthy tissue, indicate a tumor-specific activation of the immune system in patients treated with INTUVAX. Necessary regulatory approvals have now been obtained to begin recruitment of patients in several European countries.
Read the press release here: Press release 160129
Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4973